DENVER — Intravitreal sirolimus does not seem to have any systemic adverse events in the treatment of noninfectious uveitis, according to a presentation here.In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Daniel Rosberger, MD, and colleagues observed the whole-blood pharmacokinetics of intravitreal sirolimus in 14 patients who took part in the double-masked phase of the SAKURA Study 1.
DENVER — Angio-OCT may be a novel diagnostic technique to image patients with age-related macular degeneration or inflammatory affections, according to a presentation here.In a poster presented at the Association for Research in Vision and Ophthalmology annual meeting, Vittoria Ravera, MD, and colleagues evaluated the visibility of choroidal neovascularizations in a comparison of angio-OCT imaging, fluorescein angiography and indocyanine green angiography.
DENVER — visualFields easy, an iPad-based free application, may help perform visual field screening of diabetic retinopathy and glaucoma, according to a presentation here.In a presentation at the Association for Research in Vision and Ophthalmology annual meeting, Chris A. Johnson, MD, and colleagues determined the spatial characteristics and frequency of visual field deficits in more than 400 eyes in Kathmandu, Nepal, using the visualFields easy app.
NEW YORK–(BUSINESS WIRE)–Ophthotech announced that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2015 Health Care Conference on May 13, 2015.
DENVER — Patricia D’Amore, PhD, MBA, FARVO, the 2015 Proctor Medal lecturer, discussed the development of retinal vascular growth with a focus on the role of vascular endothelial growth factor in adults at the Association for Research in Vision and Ophthalmology annual meeting.“Diseases of the retina that have unwanted vessel growth really span the whole gamut [of ocular neovascularization] from prematurity to adulthood, and what we set out to do was understand how this process happens,” she said.
Clearside Biomedical and Santen, having worked together since January 2013 to develop drugs to treat retinal and choroidal diseases, announced plans to expand their collaborative relationship into glaucoma research.The expanded collaboration will focus on use of Clearside’s proprietary microinjector to deliver sustained-release formulations of IOP-lowering drugs via the suprachoroidal space, according to a joint press release from the companies.